NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IPA

ImmunoPrecise Antibodies Ltd

Jul 03 • 04:00PM ET

1.31

Dollar change +0.25
Percentage change 23.58	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP ABCL ONC ADAP FATE IGMS ANTX CABA ENTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.13	Insider Own	13.30%	Shs Outstand	45.77M	Perf Week	18.02%
Market Cap	59.95M	Forward P/E	-	EPS next Y	-0.08	Insider Trans	0.00%	Shs Float	39.68M	Perf Month	132.48%
Enterprise Value	59.96M	PEG	-	EPS next Q	-0.04	Inst Own	8.65%	Short Float	3.50%	Perf Quarter	245.46%
Income	-33.23M	P/S	3.44	EPS this Y	41.39%	Inst Trans	105.81%	Short Ratio	0.75	Perf Half Y	220.29%
Sales	17.42M	P/B	3.46	EPS next Y	82.54%	ROA	-73.58%	Short Interest	1.39M	Perf YTD	218.19%
Book/sh	0.38	P/C	6.72	EPS next 5Y	-	ROE	-121.65%	52W High	1.16 12.93%	Perf Year	34.70%
Cash/sh	0.19	P/FCF	-	EPS past 3/5Y	-32.14% -11.23%	ROIC	-132.36%	52W Low	0.27 385.19%	Perf 3Y	-67.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	9.90% 16.96%	Gross Margin	40.19%	Volatility	12.81% 17.47%	Perf 5Y	-79.85%
Dividend TTM	-	EV/Sales	3.44	EPS Y/Y TTM	-169.29%	Oper. Margin	-60.26%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.11	Sales Y/Y TTM	-0.71%	Profit Margin	-190.81%	RSI (14)	79.17	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.32	EPS Q/Q	-447.09%	SMA20	44.64%	Beta	0.50	Target Price	4.07
Payout	-	Debt/Eq	0.51	Sales Q/Q	-5.89%	SMA50	98.94%	Rel Volume	1.46	Prev Close	1.06
Employees	101	LT Debt/Eq	0.45	Earnings	Mar 28 BMO	SMA200	154.79%	Avg Volume	1.85M	Price	1.31
IPO	Nov 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	-726.70% -12.02%	Trades		Volume	2,704,609	Change	23.58%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-22	Initiated	H.C. Wainwright	Buy	$9
Oct-25-21	Initiated	The Benchmark Company	Buy	$12

Jul-06-25 04:01AM	ImmunoPrecise Antibodies' LENSai Platform Achieves Breakthrough in Epitope Mapping Accuracy (Insider Monkey)
Jul-03-25 08:19AM	ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data (Business Wire) +23.58%
Jun-24-25 07:02AM	ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai Platform Powered by Patented HYFT Technology (Business Wire)
Jun-12-25 08:01AM	AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies (Business Wire) +21.57%
Jun-05-25 08:01AM	ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery (Business Wire) +22.38%
08:49AM	Loading…
May-21-25 08:49AM	ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts (Business Wire)
May-20-25 08:28AM	ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference (Business Wire)
May-12-25 08:01AM	IPAs LENSai Platform Delivers X-RayLevel Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed (Business Wire)
Apr-11-25 08:40AM	ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai with FDA's Shift to Non-Animal Testing Methods (Business Wire) +7.56%
Apr-03-25 12:00PM	ImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -10.34%
Mar-28-25 12:59PM	ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript (Seeking Alpha) -10.97%
09:15AM	ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:01AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 (Business Wire)
Mar-27-25 05:50PM	P3 Health Partners Inc. (PIII) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Mar-13-25 07:02AM	ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. (Business Wire) +11.48%
10:17PM	Loading…
Mar-11-25 10:17PM	IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 (Business Wire) +6.14% -9.04%
Mar-05-25 08:01AM	IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 (Business Wire) +11.74%
Feb-26-25 08:01AM	IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy (Business Wire)
Feb-24-25 08:01AM	ImmunoPrecise Antibodies Announces Key Leadership Changes (Business Wire) +5.23%
Feb-20-25 08:01AM	ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period (Business Wire) -6.26%
Jan-27-25 08:01AM	ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture (Business Wire) -6.33%
Jan-23-25 07:15AM	ImmunoPrecise Antibodies develops new class of GLP-1 therapies through AI (TipRanks) -6.90%
Jan-22-25 07:02AM	IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment (Business Wire) +30.73%
Jan-17-25 08:01AM	ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation (Business Wire) -5.34%
Jan-02-25 02:55AM	ImmunoPrecise Antibodies announces resignation of CFO (TipRanks) +9.30%
Dec-31-24 07:56PM	IPA Announces Resignation of Chief Financial Officer (Business Wire)
Dec-23-24 08:30AM	ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases (Business Wire)
Dec-19-24 10:15AM	IPA to Present at The Microcap Conference 2025 (ACCESSWIRE)
Dec-10-24 08:30AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 (Business Wire)
Dec-04-24 08:00AM	IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (Business Wire)
08:30AM	Loading…
Dec-03-24 08:30AM	IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024 (Business Wire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESSWIRE)
Nov-13-24 09:00AM	$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies (Business Wire)
Nov-04-24 08:01AM	ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation (Business Wire)
Oct-28-24 07:30AM	ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology (Business Wire) -15.09%
Oct-21-24 09:00AM	ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 (Business Wire)
Oct-10-24 08:10AM	ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design (Business Wire)
Oct-09-24 03:21PM	ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ... (GuruFocus.com) -5.98%
Oct-02-24 08:00AM	ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus (Business Wire)
Sep-26-24 09:00AM	ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments (Business Wire)
Sep-16-24 09:00AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 (Business Wire) -19.12%
Sep-13-24 09:01AM	Earnings To Watch: ImmunoPrecise Antibodies Ltd (IPA) Reports Q1 2025 Result (GuruFocus.com)
Sep-09-24 09:11AM	IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 (Business Wire)
Aug-26-24 09:00AM	ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York (Business Wire)
Aug-23-24 08:00PM	ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements (Business Wire)
Aug-19-24 09:00AM	ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology (Business Wire) -5.87%
Jul-29-24 08:30AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 (Business Wire)
Jul-23-24 07:30PM	ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024 (Business Wire)
Jul-16-24 08:01PM	ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures (Business Wire) -7.14%
Jul-15-24 08:31AM	IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 (Business Wire)
Jun-27-24 08:01AM	ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer (Business Wire)
Jun-25-24 07:02AM	IPAs Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai (Business Wire)
Jun-12-24 07:00AM	ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai Technology (Business Wire)
Jun-10-24 07:15AM	BioStrand, ImmunoPrecise Antibodies Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery (Business Wire) +5.05%
Jun-04-24 07:00AM	IPAs Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) (Business Wire)
Apr-22-24 09:00AM	Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results (ACCESSWIRE)
Apr-12-24 09:00AM	ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments (ACCESSWIRE)
Mar-28-24 07:02AM	InterSystems and IPAs Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications (Business Wire)
Mar-20-24 07:02AM	IPA Acquires the Carterra LSA Instrument to Enhance Antibody Discovery and Bolster Its AI Developments (Business Wire)
Mar-15-24 01:48PM	ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2024 Earnings Call Transcript (Insider Monkey) -9.43%
Mar-14-24 12:52PM	IPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024 (InvestorPlace)
09:30AM	ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:05AM	IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* (Business Wire)
Mar-08-24 08:30AM	ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology (ACCESSWIRE)
Mar-07-24 07:02AM	IPAs subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology (Business Wire) +16.46%
Mar-04-24 08:01AM	IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024 (Business Wire) -5.85%
Feb-13-24 08:35AM	ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery (ACCESSWIRE) -8.37%
Jan-10-24 09:00AM	ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms (ACCESSWIRE) +14.08%
Dec-19-23 08:18AM	ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call Transcript (Insider Monkey)
Dec-14-23 01:51PM	IPA Stock Earnings: ImmunoPrecise Antibodies Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +20.83%
08:01AM	IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* (Business Wire)
Dec-08-23 05:00PM	IPA Announces Closing of $1.265 Million Public Offering of Common Shares (Business Wire)
Dec-07-23 09:00AM	ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14 (ACCESSWIRE)
Dec-06-23 09:00AM	Why Is ImmunoPrecise Antibodies (IPA) Stock Down 39% Today? (InvestorPlace) -24.68%
07:00AM	IPA Announces Pricing of $1.1 Million Public Offering of Common Shares (Business Wire)
Dec-05-23 04:35PM	IPA Announces Proposed Public Offering of Common Shares (Business Wire) -5.78%
Nov-27-23 08:01AM	ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call (Business Wire) +10.00%
Nov-22-23 09:00AM	ImmunoPrecises BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery (ACCESSWIRE)
Nov-13-23 08:32AM	BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research (Business Wire)
Oct-25-23 08:01AM	IPAs Subsidiary, BioStrand, Provides an Update on LENSai (Business Wire) +16.80%
Oct-23-23 08:01AM	IPA Provides Update on Growth Strategy and Recent Share Price Movement (Business Wire) +7.02%
Oct-20-23 09:00AM	Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data (ACCESSWIRE) -8.80%
Oct-13-23 09:45AM	How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research (ACCESSWIRE) -7.24%
Oct-11-23 09:55AM	ImmunoPrecise Antibodies Ltd. (IPA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) -10.43%
Sep-19-23 08:01AM	ImmunoPrecise Antibodies Announces CFO Transition (Business Wire) +6.70%
Sep-14-23 08:00AM	IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 (Business Wire)
Sep-08-23 08:30AM	IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023 (Business Wire)
Sep-05-23 08:00AM	IPA Announces Board Refreshment (Business Wire) +14.78%
Aug-09-23 09:15AM	IPA Responds to 13D Filing (Business Wire) +8.71%
Jul-14-23 08:10AM	ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research (Business Wire)
Jul-07-23 08:10AM	ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023 (Business Wire)
Jun-29-23 09:00AM	IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023. (Business Wire)
Jun-16-23 09:30AM	New to The Street Announces TV Corporate Appearances on Episodes 479 and 480 that Start Airing on Saturday, June 17, 2023, at 3:30 PM ET (GlobeNewswire)
Jun-13-23 07:38AM	IPAs Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID) (Business Wire)
Jun-06-23 08:04AM	IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market (Business Wire) -6.46%
May-30-23 08:04AM	IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology (Business Wire) +9.05%
May-17-23 08:04AM	IPA to Present at Jefferies Healthcare Conference 2023 (Business Wire)
Mar-30-23 08:04AM	ImmunoPrecises Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas (Business Wire)
Mar-27-23 08:49AM	European Patent Office to Grant BioKeys Patent Application for Foundational HYFT® Technology (Business Wire)
Mar-23-23 08:04AM	ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates (Business Wire)

ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. It owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Austin, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IPA

ImmunoPrecise Antibodies Ltd

Upgrade your FINVIZ experience